NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization30.45 mln
Float3.56 mln
Earnings Date11/09/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
23.36
Highly suspicious
1-Year Forecast
39.00
Transformational upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
0.00
Debt-free
Dividend Yield
0.00%
No dividend
Business Description
Kyntra Bio Inc., formerly FibroGen Inc., is a San Francisco-based biopharmaceutical company founded in 1993 that focuses on developing treatments for serious diseases with limited options. Its two main programs include FG-3246, an antibody-drug conjugate aimed at certain prostate and other cancers, and Roxadustat, a drug for anemia linked to chronic kidney disease and myelodysplastic syndromes that has completed late-stage clinical trials across the United States, Europe, and Japan. The company works alongside partners Astellas Pharma and AstraZeneca to advance these therapies toward patients.
